Navigation Links
RTOG activates study to determine best treatment strategies for patients with glioma brain tumors
Date:12/15/2011

Treatment remains controversial for patients diagnosed with a low-risk, low-grade glioma (LGG) brain tumor. These patients have significantly better prognosis than patients diagnosed with more aggressive high-grade glioma, and their clinical care often involves ongoing observation for tumor changes with imaging studies. Because low-risk LGG are slow growing tumors, concerns about the potential adverse effects of early treatment on patients' neurocognitive function (NCF) and quality of life (QOL) may outweigh treatment benefits in patients who are frequently young and highly functional.

Although a low-grade tumor, LGG has a significant potential for transforming into a high-grade glioma. "Currently there is no consensus on when and how best to treat this tumor," says RTOG 0925 principal investigator Ali K. Choucair, M.D., Director of Neuro-oncology and Co-director of the Brain Tumor Center at the Neuroscience Institute, Norton Healthcare System, Louisville, KY. "The RTOG 0925 study was designed with compilation of best available data from both prospective as well as retrospective studies in an effort to identify early clinical and neurocognitive changes that could precede changes observed on imaging scans and could trigger early and timely treatment," Choucair explains.

The study's goal is to better understand the affects of tumor progression on patients with low-risk LGG. The phase II trial will enroll 170 study participants with newly diagnosed LGG who are undergoing observation alone for clinical care. The study will compare NCF, QOL, and seizure control over time in patients who have evidence of tumor progression versus patients who have no evidence of progression as determined by magnetic imaging resonance (MRI) scans. "Standardized and clinically meaningful definitions of tumor progression in low-risk LGG are clearly needed to further the examination and understanding of these tumors," says Walter J. Curran, Jr., MD, RTOG Group Chair, and Executive Director of the Winship Cancer Institute of Emory University in Atlanta, "It is hoped the study's findings will help guide future treatment decisions for these patients," Curran concludes.

The study also has an important translational research component that is expected to contribute much needed information to current limited knowledge about the role molecular markers in predicting LGG tumor progression. Tumor tissue from consenting study participants will be used to evaluate molecular correlates of NCF, QOL, seizure control, and progression-free survival. Such information has the potential to aid clinical decision-making and further the identification of individualized patient therapy approaches.

Patients who have disease progression while enrolled on RTOG 0925 may be eligible for entry on a trial available to RTOG members through the NCI Clinical Trials Support Unit (CTSU) sponsored by ECOG, E3F05/RTOG 1072, Phase III Randomized Study of Radiotherapy With Versus Without Temozolomide in Patients With Symptomatic or Progressive Low-Grade Gliomas.


'/>"/>
Contact: Nancy Fredericks
nfredericks@acr.org
215-717-2769
American College of Radiology
Source:Eurekalert

Related medicine news :

1. Molecule Nutlin-3a activates a signal inducing cell death and senescence in primary brain tumors
2. Targeted therapy reactivates guardian of the genome in resistant cancer
3. Transcendental Meditation activates default mode network, the brains natural ground state
4. Arsenic exposure activates an oncogenic signaling pathway; leads to increased cancer risk
5. Heart failure study: Health-literate patients not always adept at managing care
6. Higher Hospital Admissions Equal Higher Readmissions: Study
7. Study takes aim at education-based death rate disparities
8. Study Finds Fewer Blood Transfusions Needed After Hip Surgeries
9. Wayne State study shows early research on cellphone conversations likely overestimated crash risk
10. Heart drug may be effective for managing certain cancers: Queens University study
11. Working Moms Happier, Healthier Than Stay-at-Home Peers: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... September 26, 2017 , ... SyncDog, Inc. , ... Cologne-based consultancy and software house EBF GmbH . Since 1994, EBF has ... this agreement enables SyncDog to distribute EBF Migrator product in the U.S. and ...
(Date:9/26/2017)... , ... September 26, 2017 , ... ... that is not only entirely new and different, it is scientifically proven as ... that the company has received an exclusive license agreement with BioTherapeutics Inc. for ...
(Date:9/26/2017)... ... ... Founded as an independent institute in 1968, The Glenholme School devoted ... 2018, Glenholme will celebrate its first 50 years and set a course for the ... ponies, was generously donated by Jean White Van Sinderen to Devereux in 1968. The ...
(Date:9/26/2017)... ... 26, 2017 , ... The Organizing Committee is pleased to ... Pittcon 2018. As of July 1, Adrian C. Michael, Ph.D. (University of Pittsburgh, ... Charles Gardner, (ChemImage Corporation) and selected chairs. , Other members of ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Childhood Memories of a Virginia ... readers back, and help them relive their own youth. “Childhood Memories of a Virginia ... in the US Navy for nine years. He received his BS from Idaho ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Calif. , Sept. 7, 2017  For nearly two decades, New ... in the Assisted Reproduction Insurance industry. Today, New Life Agency announces a ... medications. ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ... ...
(Date:9/6/2017)... SAN ANTONIO , Sept. 6, 2017  Robert ... as a Pinnacle Professional Member in recognition of his ... Dr. Szewc serves as a Nephrologist at the practice ... services, emergency medicine, kidney care and hypertension solutions. He ... over 20 years of career experience, as well as ...
(Date:9/5/2017)... , Sept. 5, 2017 Sapheneia and Scannerside ... solution. Scannerside DoseCheck is a third-party Vendor neutral CT ... scanners and allows compliance with current MITA standards. ... XR 29 DoseCheck solution is specifically designed to provide ... of potential radiation doses over a predefined threshold. Scannerside ...
Breaking Medicine Technology: